[September 15, 2014]

Research and Markets: Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Research and Markets (http://www.researchandmarkets.com/research/jdv9kp/brilinta_acute) has announced the addition of the "Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" report to their offering.

The current ACS (News - Alert) market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disoders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Ticagrelor was approved for use in the EU in December 2010 (AstraZeneca, press release, December 6, 2010) under the brand name Brilique. In July 2011, the FDA approved ticagrelor for use in the US under the brand name Brilinta (AstraZeneca, press release, July 20, 2011). Brilinta is indicated for use in patients during the acute phase of ACS, along with standard aspirin therapy, at a loading dose of 180mg. During the chronic treatment phase, 90mg doses are taken twice daily with maintenance doses of aspirin not to exceed 100mg.

Scope

• Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Aricept for the top seven countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Brilinta (ticagrelor)

7 Appendix

For more information visit http://www.researchandmarkets.com/research/jdv9kp/brilinta_acute

[ Back To TMCnet.com's Homepage ]